Portal de Periódicos da CAPES

Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline

2006; Cambridge University Press; Volume: 189; Issue: 2 Linguagem: Inglês

10.1192/bjp.bp.105.013045

1472-1465

Robert M. Post, Lori L. Altshuler, Gabriele S. Leverich, Mark A. Frye, Willem A. Nolen, Ralph Kupka, Trisha Suppes, Susan L. McElroy, P E Keck, Kirk D. Denicoff, Heinz Grunze, J. Walden, Christina M. Ramirez, Jim Mintz,

Treatment of Major Depression

Background Few studies have examined the relative risks of switching into hypomania or mania associated with second-generation antidepressant drugs in bipolar depression. Aims To examine the relative acute effects of bupropion, sertraline and venlafaxine as adjuncts to mood stabilisers. Method In a 10-week trial, participants receiving out-patient treatment for bipolar disorder (stratified for rapid cycling) were randomly treated with a flexible dose of one of the antidepressants, or their respective matching placebos, as adjuncts to mood stabilisers. Results A total of 174 adults with bipolar disorder I, II or not otherwise specified, currently in the depressed phase, were included. All three antidepressants were associated with a similar range of acute response (49–53%) and remission (34–41%). There was a significantly increased risk of switches into hypomania or mania in participants treated with venlafaxine compared with bupropion or sertraline. Conclusions More caution appears indicated in the use of venlafaxine rather than bupropion or sertraline in the adjunctive treatment of bipolar depression, especially if there is a prior history of rapid cycling.